Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

doi:10.5493/wjem.125753

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

(1)

(0)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Exp Med. Sep 20, 2026; 16(3): 125753
Published online Sep 20, 2026. doi: 10.5493/wjem.125753

Table 3 Univariable logistic regression: Baseline correlates of failure to reach chimeric antigen receptor T-cell infusion (n = 99; 12 events), n (%)

Variable	Not infused	Infused	OR (95%CI)	P value
Extramedullary disease	9/12 (75.0)	17/87 (19.5)	12.4 (3.0-50.6)	< 0.001
Plasma cell leukaemia	3/12 (25.0)	3/87 (3.4)	9.3 (1.6-53.4)	0.012
R-ISS stage III (vs I-II)	2/11 (18.2)	3/66 (4.5)	4.7 (0.7-31.9)	0.13
High-risk cytogenetics	4/11 (36.4)	29/85 (34.1)	1.10 (0.30-4.05)	0.88
Age (per 10 years)	Median 70.2	Median 67.7	1.24 (0.71-2.16)	0.45
Prior lines of therapy	Median 5	Median 5	-	0.431¹

¹Wilcoxon rank-sum test; not modelled. Estimates are univariable, unadjusted for multiplicity, and unstable given 12 events. No multivariable model was fitted (events per variable < 10).

CI: Confidence interval; OR: Odds ratio; R-ISS: Revised International Staging System.

Full Size Table

Citation: Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753
URL: https://www.wjgnet.com/2220-315x/full/v16/i3/125753.htm
DOI: https://dx.doi.org/10.5493/wjem.125753

Bangolo A, Gill S, Zhang L, Zhao J, Amoozgar B, Reich-Slotky R, Tran J, Vo T, Mariblanca G, Balulescu X, Mcknight S, Patel N, Reed A, Kaur S, Subramanian S, Katyal J, Manikkuttiyil C, Chakov M, Nguyen A, Pashine S, Khalil A, Mathew S, Gill R, Andrews V, Ordonez P, Olson B, Koleng M, Persaud R, Saride HS, Dharsi M, Thach R, Chen W, Shahid M, Weissman S, Siegel D, Parmar H, Biran N, Vesole DH, Phull P. Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy. World J Exp Med 2026; 16(3): 125753 [DOI: 10.5493/wjem.125753]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.